263 related articles for article (PubMed ID: 35008383)
1. Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis.
Lai CW; Xie C; Raufman JP; Xie G
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008383
[TBL] [Abstract][Full Text] [Related]
2. Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
Wei J; Yang Y; Lu M; Xu L; Liu F; Yuan Z; Bao Q; Jiang Z; Xu X; Guo X; Zhang X; You Q; Sun H
Anticancer Agents Med Chem; 2015; 16(2):174-89. PubMed ID: 26343143
[TBL] [Abstract][Full Text] [Related]
3. The regulation of MDM2 oncogene and its impact on human cancers.
Zhao Y; Yu H; Hu W
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):180-9. PubMed ID: 24389645
[TBL] [Abstract][Full Text] [Related]
4. The transcription factor MEF/Elf4 is dually modulated by p53-MDM2 axis and MEF-MDM2 autoregulatory mechanism.
Suico MA; Fukuda R; Miyakita R; Koyama K; Taura M; Shuto T; Kai H
J Biol Chem; 2014 Sep; 289(38):26143-26154. PubMed ID: 25081543
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.
Yang L; Song T; Cheng Q; Chen L; Chen J
Mol Cell Biol; 2019 Feb; 39(4):. PubMed ID: 30455251
[TBL] [Abstract][Full Text] [Related]
7. The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours?
Meek DW; Hupp TR
Semin Cancer Biol; 2010 Feb; 20(1):19-28. PubMed ID: 19897041
[TBL] [Abstract][Full Text] [Related]
8. Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2.
Nie J; Xie P; Liu L; Xing G; Chang Z; Yin Y; Tian C; He F; Zhang L
J Biol Chem; 2010 Jul; 285(30):22818-30. PubMed ID: 20484049
[TBL] [Abstract][Full Text] [Related]
9. [Progress in regulation of activity and stability of ubiquitin protein ligase MDM2].
Nie J; Tian CY
Yi Chuan; 2009 Oct; 31(10):993-8. PubMed ID: 19840920
[TBL] [Abstract][Full Text] [Related]
10. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
Lindström MS; Jin A; Deisenroth C; White Wolf G; Zhang Y
Mol Cell Biol; 2007 Feb; 27(3):1056-68. PubMed ID: 17116689
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.
Munisamy M; Mukherjee N; Thomas L; Pham AT; Shakeri A; Zhao Y; Kolesar J; Rao PPN; Rangnekar VM; Rao M
Am J Cancer Res; 2021; 11(12):5762-5781. PubMed ID: 35018225
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
Di J; Zhang Y; Zheng J
Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
[TBL] [Abstract][Full Text] [Related]
13. Regulation of p53: a collaboration between Mdm2 and Mdmx.
Pei D; Zhang Y; Zheng J
Oncotarget; 2012 Mar; 3(3):228-35. PubMed ID: 22410433
[TBL] [Abstract][Full Text] [Related]
14. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.
Xu C; Fan CD; Wang X
Oncogene; 2015 Jan; 34(3):281-9. PubMed ID: 24413081
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
Gupta A; Shah K; Oza MJ; Behl T
Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
[TBL] [Abstract][Full Text] [Related]
16. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
Nihira NT; Ogura K; Shimizu K; North BJ; Zhang J; Gao D; Inuzuka H; Wei W
Sci Signal; 2017 Feb; 10(466):. PubMed ID: 28196907
[TBL] [Abstract][Full Text] [Related]
17. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
18. The role of the MDM2/p53 axis in antitumor immune responses.
Brummer T; Zeiser R
Blood; 2024 Jun; 143(26):2701-2709. PubMed ID: 37467495
[TBL] [Abstract][Full Text] [Related]
19. Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.
Li W; Peng X; Lang J; Xu C
Front Pharmacol; 2020; 11():631. PubMed ID: 32477121
[TBL] [Abstract][Full Text] [Related]
20. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation.
Itahana K; Mao H; Jin A; Itahana Y; Clegg HV; Lindström MS; Bhat KP; Godfrey VL; Evan GI; Zhang Y
Cancer Cell; 2007 Oct; 12(4):355-66. PubMed ID: 17936560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
